Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors.